These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18158035)

  • 1. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
    Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ
    Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is prostate-specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?
    Jones TD; Koch MO; Bunde PJ; Cheng L
    BJU Int; 2006 Mar; 97(3):480-4. PubMed ID: 16469012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
    Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
    Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
    Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
    Sim HG; Telesca D; Culp SH; Ellis WJ; Lange PH; True LD; Lin DW
    J Urol; 2008 May; 179(5):1775-9. PubMed ID: 18343432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
    Nguyen PL; Chen MH; Catalona WJ; Alexander BM; Roehl KA; Loeb S; D'Amico AV
    Cancer; 2008 Dec; 113(11):3146-52. PubMed ID: 18932254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
    Zhu H; Roehl KA; Antenor JA; Catalona WJ
    Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics of prostatic cancer in men with a serum prostate-specific antigen level of < or =4.0 ng/ml].
    Ono Y; Chiba K; Tanaka H
    Hinyokika Kiyo; 2005 Oct; 51(10):647-50. PubMed ID: 16285616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
    Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.